Entrada Therapeutics, Inc.
Company Stats
- Market Cap
- $247.2M
- as of Sep 30, 2026
- Shares Outstanding
- 38.9M
- Free Float
- 50.0%
Income Statement
- Revenue
- $25.4M
- Operating Income
- -$157.9M
- Net Income
- -$143.8M
- EBITDA
- -$153.8M
- FCF Margin, 3Y Avg
- -142.3%
- FCF Margin, Worst Year
- -509.6%
Cash Flow
- Free Cash Flow
- -$129.6M
- FCF Yield
- -52.4%
- Owner FCF Yield
- -60.3%
Balance Sheet
- Cash & Equivalents
- $90.4M
Returns & Capital
- SBC, 3Y Avg
- $16.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $25.4M | -$129.6M | -509.6% |
| FY2024 | $210.8M | -$44.7M | -21.2% |
| FY2023 | $129.0M | $134.2M | 104.0% |
| FY2022 | — | -$96.7M | — |
| FY2021 | — | -$55.4M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back